Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZH901 for steroid-refractory pediatric acute graft-versus-host disease
ChiCTR2600133408Phase 2Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Oct 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of CAStem in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: Overall Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CAStem
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2600133408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133408.